T. Rowe Price Associates’s Pulmonx LUNG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $26K | Hold |
19,884
| – | – | ﹤0.01% | 3109 |
|
|
2025
Q4 | $44K | Hold |
19,884
| – | – | ﹤0.01% | 3044 |
|
|
2025
Q3 | $33K | Sell |
19,884
-17,846
| -47% | -$37.3K | ﹤0.01% | 3026 |
|
|
2025
Q2 | $98K | Buy |
37,730
+1,588
| +4% | +$6.26K | ﹤0.01% | 2896 |
|
|
2025
Q1 | $244K | Buy |
36,142
+2,557
| +8% | +$18.1K | ﹤0.01% | 2551 |
|
|
2024
Q4 | $229K | Sell |
33,585
-9,423
| -22% | -$62K | ﹤0.01% | 2626 |
|
|
2024
Q3 | $357K | Buy |
43,008
+299
| +0.7% | +$2.16K | ﹤0.01% | 2401 |
|
|
2024
Q2 | $271K | Buy |
42,709
+6,989
| +20% | +$53.7K | ﹤0.01% | 2462 |
|
|
2024
Q1 | $332K | Buy |
35,720
+1,633
| +5% | +$19.1K | ﹤0.01% | 2390 |
|
|
2023
Q4 | $435K | Buy |
34,087
+580
| +2% | +$6.04K | ﹤0.01% | 2236 |
|
|
2023
Q3 | $347K | Buy |
33,507
+3,749
| +13% | +$43.4K | ﹤0.01% | 2280 |
|
|
2023
Q2 | $391K | Buy |
29,758
+2,963
| +11% | +$36.2K | ﹤0.01% | 2247 |
|
|
2023
Q1 | $300K | Buy |
26,795
+691
| +3% | +$6.82K | ﹤0.01% | 2343 |
|
|
2022
Q4 | $220K | Buy |
26,104
+708
| +3% | +$6.73K | ﹤0.01% | 2492 |
|
|
2022
Q3 | $424K | Buy |
25,396
+2,033
| +9% | +$37.4K | ﹤0.01% | 2210 |
|
|
2022
Q2 | $344K | Buy |
23,363
+2,377
| +11% | +$49K | ﹤0.01% | 2387 |
|
|
2022
Q1 | $521K | Sell |
20,986
-197
| -0.9% | -$5.09K | ﹤0.01% | 2321 |
|
|
2021
Q4 | $679K | Sell |
21,183
-390,204
| -95% | -$14.3M | ﹤0.01% | 2235 |
|
|
2021
Q3 | $14.8M | Buy |
411,387
+21,860
| +6% | +$860K | ﹤0.01% | 1366 |
|
|
2021
Q2 | $17.2M | Sell |
389,527
-328,396
| -46% | -$14.3M | ﹤0.01% | 1335 |
|
|
2021
Q1 | $32.8M | Buy |
717,923
+348,008
| +94% | +$20M | ﹤0.01% | 1149 |
|
|
2020
Q4 | $25.5M | Buy |
+369,915
| New | +$18.1M | ﹤0.01% | 1159 |
|
Other funds holding LUNG
SCM
ECM
VCM
